The long-term success of national efforts to reduce breast cancer incidence and mortality rests in part on the ability of Breast Cancer SPORE programs to attract and build the translational research careers of talented young faculty and to redirect senior faculty to breast cancer research. For the past fourteen years, the UNC Breast Cancer SPORE has effectively used career development funds to promote the breast cancer research careers of selected investigators. Participants in the SPORE career development program (CDP) have contributed to the national breast cancer effort and established long-term careers as translational breast cancer researchers. Their contributions include published research, funded grants focused on breast cancer, participation in collaborative breast cancer research and leadership within the SPORE program itself. CDP participants have become an integral part of the UNC Breast Cancer SPORE. Seven CDP alumni (Drs. Carey, Dees, Klauber-DeMore, Livasy, Millikan, Perou Sartor) serve as co-leaders on the projects and core facilities in this application; each of the five proposed SPORE projects has a CDP alum as co-leader. As a result of the Breast Cancer SPORE, all seven investigators are now firmly established as translational breast cancer researchers, each with distinct interests, collaborations, and honors. Over the next five years, the UNC Breast Cancer SPORE will continue to promote and develop careers in translational breast cancer research. We request SPORE support of $50,000 per year to combine with $50,000 in institutional funds to provide $100,000 total in flexible funds for career development. The SPORE will use these funds in three categories: 1) to help recruit and develop junior faculty with translational breast cancer research programs; 2) to provide salary support for senior faculty at UNC developing breast cancer research interests or projects; and 3) to attract more senior faculty from other institutions by offering funded leaves of three to twelve months to develop or enhance a breast cancer research focus. For Year 15, the SPORE proposes to support the development of two junior faculty interested in translational breast cancer research: Pilar Blancafort, PhD and Jeffrey Peppercorn, MD. CDP candidates will take advantage of the research and training opportunities available at UNC through the SPORE, the Cancer Center, and the University at large. Working with pre-, postdoctoral, and faculty training programs in the clinical, basic and population sciences, the UNC Breast Cancer SPORE offers unique development opportunities. Fellows and junior faculty can obtain world-class mentoring to fine tune career directions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-16
Application #
7663918
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
16
Fiscal Year
2008
Total Cost
$70,690
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Nasarre, Patrick; Bonilla, Ingrid V; Metcalf, John S et al. (2018) TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res 28:185-194
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Couture, Heather D; Williams, Lindsay A; Geradts, Joseph et al. (2018) Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer 4:30

Showing the most recent 10 out of 598 publications